The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL),Hyderabad.
- 2-DG halts the spread of COVID-19 inside the body cells.
- Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
- In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints.
- A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalisation of specific vital signs parameters when compared to SoC.
- The Drugs Controller General of India approved an anti-COVID oral drug, developed by DRDO, for emergency use as adjunct therapy in moderate to severe coronavirus patients based on this compound.
- The drug comes in powder form in sachet, which is taken orally by dissolving it in water. Clinical trial results have shown that 2-DG helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
How 2-DG reduces dependence on oxygen
- The 2 DG drug, like glucose, spreads through the body, reaches the virus-infected cells and prevents virus growth by stopping viral synthesis and destroys the protein’s energy production.
- The drug also works on virus infection spread into lungs which help us to decrease patients dependability on oxygen.
Science and Technology Current Affairs : Click Here